A phase 2, multi-center, double-blind, placebo controlled, dose-ranging study to evaluate the safety, tolerability, and efficacy of LymphoStat-B antibody (monoclonal anti-BLyS antibody) [belimumab; Human Genome Sciences] in subjects with rheumatoid arthritis (RA).

Trial Profile

A phase 2, multi-center, double-blind, placebo controlled, dose-ranging study to evaluate the safety, tolerability, and efficacy of LymphoStat-B antibody (monoclonal anti-BLyS antibody) [belimumab; Human Genome Sciences] in subjects with rheumatoid arthritis (RA).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2013

At a glance

  • Drugs Belimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Sep 2011 Planned end date of the extension trial (NCT00931086) is Dec 2011.
    • 13 Sep 2011 Actual initation date of the extension trial (NCT00931086) is Apr 2009.
    • 13 Sep 2011 Status of the extension trial (NCT00931086) is active no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top